ZNF198 antibody
GTX105550
ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetZMYM2
Overview
- SupplierGeneTex
- Product NameZNF198 antibody
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. ICC/IF: 1:50-1:500. IHC-P: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration0.57 mg/ml
- ConjugateUnconjugated
- Gene ID7750
- Target nameZMYM2
- Target descriptionzinc finger MYM-type containing 2
- Target synonymsFIM, MYM, NECRC, RAMP, SCLL, ZNF198, zinc finger MYM-type protein 2, fused in myeloproliferative disorders protein, rearranged in an atypical myeloproliferative disorder, zinc finger protein 198, zinc finger, MYM-type 2
- HostRabbit
- IsotypeIgG
- Protein IDQ9UBW7
- Protein NameZinc finger MYM-type protein 2
- Scientific DescriptionThe protein encoded by this gene is a zinc finger protein that may act as a transcription factor. The encoded protein may be part of a BHC histone deacetylase complex. Translocation of this gene with the fibroblast growth factor receptor-1 gene (FGFR1) results in a fusion gene, which may be a cause of stem cell leukemia lymphoma syndrome (SCLL). Several transcript variants encoding the same protein have been found for this gene. [provided by RefSeq]
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Yamanaka S, Furihata H, Yanagihara Y, et al. Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation. Nat Commun. 2023,14(1):4683. doi: 10.1038/s41467-023-40385-9Read this paper
- Yamanaka S, Horiuchi Y, Matsuoka S, et al. A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues. Nat Commun. 2022,13(1):183. doi: 10.1038/s41467-021-27818-zRead this paper




